Polymer Delivery Systems for Long-Acting Antiretroviral Drugs

Mohammad Ullah Nayan; Sudipta Panja; Ashrafi Sultana; Lubaba A. Zaman; Lalitkumar K. Vora; Brady Sillman; Howard E. Gendelman; Benson Edagwa

doi:10.3390/pharmaceutics16020183

Polymer Delivery Systems for Long-Acting Antiretroviral Drugs

Mohammad Ullah Nayan, Sudipta Panja, Ashrafi Sultana, Lubaba A. Zaman, Lalitkumar K. Vora, Brady Sillman, Howard E. Gendelman, Benson Edagwa

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

The success of long-acting (LA) drug delivery systems (DDSs) is linked to their biocompatible polymers. These are used for extended therapeutic release. For treatment or prevention of human immune deficiency virus type one (HIV-1) infection, LA DDSs hold promise for improved regimen adherence and reduced toxicities. Current examples include Cabenuva, Apretude, and Sunlenca. Each is safe and effective. Alternative promising DDSs include implants, prodrugs, vaginal rings, and microarray patches. Each can further meet patients’ needs. We posit that the physicochemical properties of the formulation chemical design can optimize drug release profiles. We posit that the strategic design of LA DDS polymers will further improve controlled drug release to simplify dosing schedules and improve regimen adherence.

Original language	English (US)
Article number	183
Journal	Pharmaceutics
Volume	16
Issue number	2
DOIs	https://doi.org/10.3390/pharmaceutics16020183
State	Published - Feb 2024

Keywords

HIV
antiretroviral therapy
chronic infectious diseases
implants
long-acting formulations
microarray patches
polymer
prodrug nanoformulations
vaginal rings

ASJC Scopus subject areas

Pharmaceutical Science

Access to Document

10.3390/pharmaceutics16020183

Cite this

@article{97dd85bf9b884272b11d166769804325,

title = "Polymer Delivery Systems for Long-Acting Antiretroviral Drugs",

abstract = "The success of long-acting (LA) drug delivery systems (DDSs) is linked to their biocompatible polymers. These are used for extended therapeutic release. For treatment or prevention of human immune deficiency virus type one (HIV-1) infection, LA DDSs hold promise for improved regimen adherence and reduced toxicities. Current examples include Cabenuva, Apretude, and Sunlenca. Each is safe and effective. Alternative promising DDSs include implants, prodrugs, vaginal rings, and microarray patches. Each can further meet patients{\textquoteright} needs. We posit that the physicochemical properties of the formulation chemical design can optimize drug release profiles. We posit that the strategic design of LA DDS polymers will further improve controlled drug release to simplify dosing schedules and improve regimen adherence.",

keywords = "HIV, antiretroviral therapy, chronic infectious diseases, implants, long-acting formulations, microarray patches, polymer, prodrug nanoformulations, vaginal rings",

author = "Nayan, {Mohammad Ullah} and Sudipta Panja and Ashrafi Sultana and Zaman, {Lubaba A.} and Vora, {Lalitkumar K.} and Brady Sillman and Gendelman, {Howard E.} and Benson Edagwa",

note = "Publisher Copyright: {\textcopyright} 2024 by the authors.",

year = "2024",

month = feb,

doi = "10.3390/pharmaceutics16020183",

language = "English (US)",

volume = "16",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "2",

}

TY - JOUR

T1 - Polymer Delivery Systems for Long-Acting Antiretroviral Drugs

AU - Nayan, Mohammad Ullah

AU - Panja, Sudipta

AU - Sultana, Ashrafi

AU - Zaman, Lubaba A.

AU - Vora, Lalitkumar K.

AU - Sillman, Brady

AU - Gendelman, Howard E.

AU - Edagwa, Benson

PY - 2024/2

Y1 - 2024/2

N2 - The success of long-acting (LA) drug delivery systems (DDSs) is linked to their biocompatible polymers. These are used for extended therapeutic release. For treatment or prevention of human immune deficiency virus type one (HIV-1) infection, LA DDSs hold promise for improved regimen adherence and reduced toxicities. Current examples include Cabenuva, Apretude, and Sunlenca. Each is safe and effective. Alternative promising DDSs include implants, prodrugs, vaginal rings, and microarray patches. Each can further meet patients’ needs. We posit that the physicochemical properties of the formulation chemical design can optimize drug release profiles. We posit that the strategic design of LA DDS polymers will further improve controlled drug release to simplify dosing schedules and improve regimen adherence.

AB - The success of long-acting (LA) drug delivery systems (DDSs) is linked to their biocompatible polymers. These are used for extended therapeutic release. For treatment or prevention of human immune deficiency virus type one (HIV-1) infection, LA DDSs hold promise for improved regimen adherence and reduced toxicities. Current examples include Cabenuva, Apretude, and Sunlenca. Each is safe and effective. Alternative promising DDSs include implants, prodrugs, vaginal rings, and microarray patches. Each can further meet patients’ needs. We posit that the physicochemical properties of the formulation chemical design can optimize drug release profiles. We posit that the strategic design of LA DDS polymers will further improve controlled drug release to simplify dosing schedules and improve regimen adherence.

KW - HIV

KW - antiretroviral therapy

KW - chronic infectious diseases

KW - implants

KW - long-acting formulations

KW - microarray patches

KW - polymer

KW - prodrug nanoformulations

KW - vaginal rings

UR - http://www.scopus.com/inward/record.url?scp=85185950918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85185950918&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics16020183

DO - 10.3390/pharmaceutics16020183

M3 - Review article

C2 - 38399244

AN - SCOPUS:85185950918

SN - 1999-4923

VL - 16

JO - Pharmaceutics

JF - Pharmaceutics

IS - 2

M1 - 183

ER -

Polymer Delivery Systems for Long-Acting Antiretroviral Drugs

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this